Overview of the Global Alzheimer’s Therapeutics Market
The author's market research report predicts that the “Global Alzheimer’s Therapeutics Market” will grow at a CAGR of ~7.0% during the forecast period. The market has witnessed steady growth in the past few years and is sustaining due to an increase in geriatric population and promising pipeline in development.
Estimates are diverse, but specialists indicate that up to 5.5 million Americans aged 65 and above could have Alzheimer's disease. Increase in geriatric population and promising pipeline in development is anticipated to boost the market growth. Emerging novel diagnostic technologies and investment in biomarkers for drug development are providing an opportunity for the development of the market. However, failures of late-stage drugs and restricted awareness about Alzheimer’s disease are hampering the market growth.
The majority of the revenue is generated from the leading players in the market with dominating sales of Eisai Co. Ltd, Novartis AG, Pfizer Inc., Eli Lilly & Company, Johnson & Johnson, Daiichi Sankyo Company Limited, F. Hoffmann-La Roche, H. Lundbeck A/S, TauRx Therapeutics Ltd, and Allergan.
According to the analysis, North America accounted for the largest share of the global Alzheimer’s therapeutics market in 2018. The Asia Pacific region is expected to witness the fastest growth rate due to the large patient pool and rising healthcare expenditure.
By Molecule Type:
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
By End Users:
- Hospital Pharmacies
- Retail Pharmacies
- North America
Alzheimer’s Therapeutics Market Research Competitive Analysis – The Federal Government has led study initiatives on Alzheimer's disease by the National Institute for Aging (NIA) at National Institutes for Health (NIH). Diverse variety of research is carried out through NIA-supported Alzheimer Research Centers across the US, which includes study of the causes, diagnosis and treatment, and management of the disease. NIA also supports the Alzheimer Clinical Trials Consortium which is intended to speed up and grow Alzheimer and associated dementia research and therapies. The NIH donated about $589 million in 2015 to AD study initiatives, which includes the Alzheimer's Association, the National Health Institute (NIH), and the Federal Ministry of Health.
- Eisai Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Eli Lilly & Company
- Johnson & Johnson
- Leading products like Aricept, Exelon, and Reminyl dominate the industry; Aricept with a cholinesterase inhibitor as its active component has the biggest business share in it.
- There is an increase in combination therapy recommended to the patients with Alzheimer’s disease.
The report provides complete details about the sub-segments of the Alzheimer’s therapeutics market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.
- Understanding the potential market opportunity with precise market size and forecast data.
- A detailed market analysis focusing on the growth of Alzheimer’s therapeutics industry.
- Factors influencing the growth of the Alzheimer’s therapeutics market.
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the Alzheimer’s therapeutics market in both developed and developing regions.
- Key insights related to major segments of the Alzheimer’s therapeutics market.
- Latest market trend analysis impacting the buying behavior of consumers.
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 Pharmaceutical Spending Region Wise
1.1.3 R&D Pipeline in Pharmaceutical Industry
1.1.4 Top Pharma Drugs by Sales in 2017 ($Million)
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Parkinson’s Disease
4 Market Outlook
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
220.127.116.11 Promising pipeline in development
18.104.22.168 Increase in geriatric population
22.214.171.124 Failures of late-stage drugs
126.96.36.199 Restricted awareness about Alzheimer’s disease
188.8.131.52 Emerging novel diagnostic technologies
184.108.40.206 Investment in biomarkers for drug development
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6 Molecule Type: Market Size and Analysis
6.2 Cholinesterase Inhibitors
6.3 NMDA Receptor Antagonists
7 Distribution Channel: Market Size and Analysis
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 E Pharmacies
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendors Profile
10.1 Novartis AG
10.2 Eisai Co. Ltd.
10.3 Pfizer Inc.
10.4 Eli Lilly & Company
10.5 Johnson & Johnson
11 Companies to Watch for
11.1 Daiichi Sankyo Company Ltd
11.2 F. Hoffmann-La Roche
11.3 H. Lundbeck A/S
11.4 TauRx Therapeutics Ltd
List of Tables
- Alzheimer’S Therapeutics Market Revenue, By Product, 2018–2025 ($Million)
- Alzheimer’S Therapeutics Market Revenue, By Type, 2018–2025 ($Million)
- Alzheimer’S Therapeutics Market Revenue, By Geography, 2018–2025 ($Million)
- Business Summary: Novartis Ag
- Business Summary: Eisai Co. Ltd
- Business Summary: Pfizer Inc
- Business Summary: Eli Lilly & Company
- Business Summary: Johnson & Johnson
- Business Summary: Daiichi Sankyo Company Ltd
- Business Summary: F. Hoffmann-La Roche
- Business Summary: H. Lundbeck A/S
- Business Summary: Taurx Therapeutics Ltd
- Global Pharmaceutical R&D Spending (2010–2016)
- Estimated R&D Investment By Top 10 Companies ($Bn)
- Research Methodology Of Global Alzheimer’S Therapeutics Market
- Global Alzheimer’S Therapeutics Market Revenue, 2018–2025 ($Million)
- Global Alzheimer’S Therapeutics Market Segmentation
- Porters 5 Forces On Global Alzheimer’S Therapeutics Market
- Pest Analysis Of Global Alzheimer’S Therapeutics Market
- Market Dynamics – Drivers, Restraints & Opportunities
- Dro - Impact Analysis Of Global Alzheimer’S Therapeutics Market
- Key Stakeholders Of Global Alzheimer’S Therapeutics Market
- Global Alzheimer’S Therapeutics Market Revenue, By Product, 2018 ($Million)
- Cholinesterase Inhibitors Market Revenue, 2018–2025 ($Million)
- Nmda Receptor Antagonists Market Revenue, 2018–2025 ($Million)
- Others Market Revenue, 2018–2025 ($Million)
- Global Alzheimer’S Therapeutics Market Revenue, By Distribution Channel, 2018–2025 ($Million)
- Hospital Pharmacies Market Revenue, 2018–2025 ($Million)
- Retail Pharmacies Market Revenue, 2018–2025 ($Million)
- E Pharmacies Market Revenue, 2018–2025 ($Million)
- Global Alzheimer’S Therapeutics Market By Regional Segmentation, 2018 (%)
- Global Alzheimer’S Therapeutics Market By Regional Segmentation, 2025 (%)
- Alzheimer’S Therapeutics Market Revenue In North America, 2018–2025 ($Million)
- Alzheimer’S Therapeutics Market Revenue In Europe, 2018–2025 ($Million)
- Alzheimer’S Therapeutics Market Revenue In Asia Pacific, 2018–2025 ($Million)
- Alzheimer’S Therapeutics Market Revenue In Rest Of The World, 2018–2025 ($Million)